cyclosporine has been researched along with Dyslipidemia in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (30.43) | 29.6817 |
| 2010's | 14 (60.87) | 24.3611 |
| 2020's | 2 (8.70) | 2.80 |
| Authors | Studies |
|---|---|
| Armstrong, AW; Connor, C; Cordoro, KM; Davis, DMR; Elewski, BE; Elmets, CA; Farley Prater, EA; Gelfand, JM; Gordon, KB; Gottlieb, AB; Hariharan, V; Kaplan, DH; Kavanaugh, A; Kiselica, M; Kivelevitch, D; Korman, NJ; Kroshinsky, D; Lebwohl, M; Leonardi, CL; Lichten, J; Lim, HW; Mehta, NN; Menter, A; Paller, AS; Parra, SL; Pathy, AL; Rupani, RN; Siegel, M; Stoff, B; Strober, BE; Wong, EB; Wu, JJ | 1 |
| Asai, R; Kaneko, T; Seki, M; Tsuruoka, S | 1 |
| Albhaisi, S; Arshad, T; Bhati, C; Driscoll, C; Lee, E; Patel, S; Reichman, T; Siddiqui, MB; Siddiqui, MS; Wolver, S | 1 |
| Berhoune, A; Boukni, H; Chettouh, H; Mokhtari, N; Yargui, L | 1 |
| Holdaas, H; Potena, L; Saliba, F | 1 |
| Eriksson, JW; Pereira, MJ; Svensson, MK | 1 |
| Akhtar, SF; Fazal, MA; Idrees, MK | 1 |
| Abe, T; Ichimaru, N; Imamura, R; Kaimori, JY; Kakuta, Y; Kato, T; Nonomura, N; Takahara, S; Yamanaka, K | 1 |
| Boillot, O; Collardeau-Frachon, S; Di Filippo, M; Dumortier, J; Lachaux, A; Peretti, N; Rivet, C; Roblin, E; Sassolas, A; Serusclat, A | 1 |
| Dedinska, I; Krejci, K; Lackova, E; Roland, R; Zadrazil, J; Zilinska, Z | 1 |
| Cuervas-Mons, V; D'Avola, D; Fábrega, E; Fraga, E; Gómez, MA; Herrero, JI; Jimenez, C; Lladó, L; Lopez, P; Martí, J; Ortiz de Urbina, J; Otero, E; Rios, A; Rodrigo, JM; Serrano, MT; Suarez, F | 1 |
| Aliabadi, AZ; Dunkler, D; Grimm, M; Grömmer, M; Mahr, S; Wolner, E; Zimpfer, D; Zuckermann, AO | 1 |
| Aranda Narváez, JM; Fernández Aguilar, JL; González Sánchez, AJ; Pérez Daga, JA; Sánchez Pérez, B; Santoyo Santoyo, J; Suárez Muñoz, MA | 1 |
| Hoskova, L; Kautzner, J; Kubanek, M; Malek, I; Podzimkova, M; Skalicka, B; Vymetalova, Y | 1 |
| Begliomini, B; Codeluppi, M; Di Benedetto, F; Gerring, R; Gerunda, GE; Masetti, M; Montalti, R; Romano, A; Rompianesi, G | 1 |
| Borda, B; Eller, J; Hódi, Z; Lázár, G; Lengyel, C; Marofka, F; Morvay, Z; Szabó, V; Szederkényi, E; Szenohradszky, P; Takács, T | 1 |
| Fang, CH; Jiang, Y; Lan, GB; Peng, FH; Peng, LK; Wang, Y; Xie, XB; Yu, SJ | 1 |
| Brown, R; Burke, GW; Chen, L; Ciancio, G; Gaynor, JJ; Guerra, G; Hanson, L; Kupin, W; Livingstone, AS; Roth, D; Ruiz, P; Sageshima, J; Tueros, L; Zarak, A | 1 |
| Felipe, CR; Mandia-Sampaio, EL; Medina-Pestana, JO; Park, SI; Spinelli, GA; Tedesco-Silva, H | 1 |
| Chong, G; Cristol, JP; Deleuze, S; Delmas, S; Garrigue, V; Mourad, G; Swarcz, I | 1 |
| Azevedo, E; Burton, J; Davies, R; Ferguson, R; Genest, J; Giannetti, N; Haddad, H; Isaac, D; LeBlanc, MH; Pflugfelder, P; Racine, N; Ross, H; White, M | 1 |
| Garcia, VD; Keitel, E; Piovesan, F; Pozza, R; Saitovitch, D; Santos, AF; Sarturi, PS; Tognon, A; Veronese, FJ | 1 |
| Boccalini, F; Castagneto, M; Citterio, F; Fioravanti, G; Navarra, P; Pozzetto, U | 1 |
1 review(s) available for cyclosporine and Dyslipidemia
| Article | Year |
|---|---|
mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern?
Topics: Calcineurin Inhibitors; Cyclosporine; Dyslipidemias; Everolimus; Graft Rejection; Humans; Immunosuppressive Agents; Organ Transplantation; TOR Serine-Threonine Kinases | 2015 |
4 trial(s) available for cyclosporine and Dyslipidemia
| Article | Year |
|---|---|
Dyslipidaemia among renal transplant recipients: cyclosporine versus tacrolimus.
Topics: Adult; Cyclosporine; Dyslipidemias; Female; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Tacrolimus; Young Adult | 2014 |
Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function.
Topics: Adult; Calcineurin Inhibitors; Cyclosporine; Dyslipidemias; Everolimus; Female; Humans; Immunosuppressive Agents; Kidney Function Tests; Liver Transplantation; Male; Middle Aged; Renal Insufficiency; Sirolimus | 2010 |
Randomized trial of immunosuppressive regimens in renal transplantation.
Topics: Adolescent; Adult; Aged; Cyclosporine; Diabetes Mellitus; Drug Therapy, Combination; Dyslipidemias; Female; Florida; Graft Rejection; Guideline Adherence; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Infections; Kidney Function Tests; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Sirolimus; Young Adult | 2011 |
Subclinical inflammation and prothrombotic state in heart transplant recipients: impact of cyclosporin microemulsion vs. tacrolimus.
Topics: Adult; Aged; Biomarkers; Blood Pressure; C-Reactive Protein; Cyclosporine; Dyslipidemias; Emulsions; Heart Transplantation; Hemostasis; Humans; Immunosuppressive Agents; Inflammation; Middle Aged; Postoperative Complications; Tacrolimus; Thrombosis | 2006 |
18 other study(ies) available for cyclosporine and Dyslipidemia
| Article | Year |
|---|---|
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients.
Topics: Adolescent; Adrenal Cortex Hormones; Anthralin; Biological Products; Calcineurin Inhibitors; Cardiovascular Diseases; Child; Child, Preschool; Coal Tar; Comorbidity; Cyclosporine; Dermatologic Agents; Dyslipidemias; Evidence-Based Medicine; Humans; Infant; Infant, Newborn; Inflammatory Bowel Diseases; Insulin Resistance; Mental Health; Metabolic Syndrome; Methotrexate; Nicotinic Acids; Obesity; Photochemotherapy; Psoriasis; Retinoids | 2020 |
Effective improvement of minimal change nephrotic syndrome with uncontrollable high low-density lipoprotein cholesterol level using evolocumab accompanied by the development of acute pancreatitis.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Asian People; Cholesterol, LDL; Cyclosporine; Drug Therapy, Combination; Dyslipidemias; Female; Fluid Therapy; Humans; Immunosuppressive Agents; Injections, Subcutaneous; Middle Aged; Nephrosis, Lipoid; Pancreatitis; PCSK9 Inhibitors; Proprotein Convertase 9; Remission Induction; Severity of Illness Index | 2020 |
The Relationship Between Hypoadiponectinemia and Cardiovascular Events in Liver Transplant Recipients.
Topics: Adiponectin; Aged; Cardiovascular Diseases; Cyclosporine; Diabetes Complications; Dyslipidemias; End Stage Liver Disease; Female; Humans; Immunosuppression Therapy; Insulin Resistance; Liver Transplantation; Male; Metabolism, Inborn Errors; Middle Aged; Obesity; Proportional Hazards Models; Prospective Studies; Risk Assessment; Tacrolimus; Transplant Recipients; Treatment Outcome | 2019 |
Metabolic status of 1088 patients after renal transplantation: assessment of twelve years monitoring in Algiers Mustapha Hospital.
Topics: Adult; Algeria; Biomarkers; Blood Glucose; Chi-Square Distribution; Cyclosporine; Diabetes Mellitus; Drug Monitoring; Dyslipidemias; Female; Hospitals; Humans; Immunosuppressive Agents; Kidney; Kidney Transplantation; Lipids; Male; Middle Aged; Retrospective Studies; Tacrolimus; Time Factors; Treatment Outcome; Young Adult | 2014 |
A case report of improved metabolic control after conversion from everolimus to cyclosporin A: role of adipose tissue mechanisms?
Topics: Adipose Tissue; Aged; Cyclosporine; Diabetes Mellitus; Dyslipidemias; Everolimus; Female; Glucose; Humans; Immunosuppressive Agents; Kidney Transplantation; Sirolimus; TOR Serine-Threonine Kinases | 2014 |
Risk factors and incidence for lipid abnormalities in kidney transplant patients.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Azathioprine; Cyclosporine; Dyslipidemias; Everolimus; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Kidney Transplantation; Lipids; Male; Middle Aged; Mycophenolic Acid; Ribonucleosides; Risk Factors; Tacrolimus | 2015 |
Lipid profile and cardiovascular risk factors in pediatric liver transplant recipients.
Topics: Adolescent; Apolipoprotein A-I; Apolipoproteins B; Biopsy; Cardiovascular Diseases; Child; Child, Preschool; Cholesterol, HDL; Cholesterol, LDL; Cyclosporine; Dyslipidemias; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Infant; Liver; Liver Failure; Liver Transplantation; Male; Retrospective Studies; Risk Factors; Tacrolimus; Transplant Recipients; Treatment Outcome | 2016 |
Clinical experience of conversion from cyclosporine to tacrolimus prolonged-release in stabilized kidney transplant patients.
Topics: Cyclosporine; Delayed-Action Preparations; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Substitution; Dyslipidemias; Female; Gingival Hyperplasia; Glomerular Filtration Rate; Hirsutism; Humans; Hypertension, Renal; Immunosuppressive Agents; Kidney Diseases; Kidney Transplantation; Male; Middle Aged; Tacrolimus; Treatment Outcome | 2016 |
Cardiovascular morbidity and mortality after liver transplantation: The protective role of mycophenolate mofetil.
Topics: Adult; Age Factors; Aged; Cardiovascular Diseases; Cyclosporine; Diabetes Mellitus, Type 1; Dyslipidemias; End Stage Liver Disease; Female; Follow-Up Studies; Graft Rejection; Humans; Hypertension; Immunosuppressive Agents; Liver Transplantation; Male; Metabolic Syndrome; Middle Aged; Mycophenolic Acid; Postoperative Complications; Prevalence; Prospective Studies; Risk Factors; Severity of Illness Index; Spain; Survival Analysis; Tacrolimus; Transplant Recipients | 2017 |
Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation.
Topics: Adrenal Cortex Hormones; Aged; Atorvastatin; Cholesterol; Cyclosporine; Dyslipidemias; Female; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Postoperative Complications; Pravastatin; Pyrroles; Safety; Sirolimus; Treatment Outcome; Triglycerides | 2008 |
Adverse effects on the lipid profile of immunosuppressive regimens: tacrolimus versus cyclosporin measured using C2 levels.
Topics: Cyclosporine; Dyslipidemias; Female; Humans; Hypercholesterolemia; Hypertriglyceridemia; Immunosuppressive Agents; Lipids; Liver Transplantation; Male; Tacrolimus | 2009 |
Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cohort Studies; Cyclosporine; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heart Transplantation; Heptanoic Acids; Humans; Immunosuppressive Agents; Indoles; Male; Middle Aged; Prospective Studies; Pyrroles; Tacrolimus; Treatment Outcome; Triglycerides | 2009 |
Functional and histopathologic changes in renal transplant patients with new-onset diabetes and dyslipidemia.
Topics: Adult; Analysis of Variance; Atrophy; Biomarkers; Biopsy; Body Mass Index; Case-Control Studies; Chi-Square Distribution; Creatinine; Cyclosporine; Diabetes Mellitus; Dyslipidemias; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Graft Survival; Humans; Hungary; Immunosuppressive Agents; Kidney; Kidney Transplantation; Lipids; Logistic Models; Male; Middle Aged; Retrospective Studies; Risk Assessment; Risk Factors; Tacrolimus; Time Factors; Treatment Outcome | 2011 |
Dyslipidemia in human kidney transplant recipients receiving cyclosporine and tacrolimus is associated with different expression of CD36 on peripheral blood monocytes.
Topics: Adult; CD36 Antigens; Cyclosporine; Dyslipidemias; Female; Humans; Kidney Transplantation; Male; Middle Aged; Monocytes; Tacrolimus | 2011 |
Lipid profile changes during the first year after kidney transplantation: risk factors and influence of the immunosuppressive drug regimen.
Topics: Adult; Analysis of Variance; Biomarkers; Brazil; Chi-Square Distribution; Cyclosporine; Drug Therapy, Combination; Dyslipidemias; Everolimus; Female; Humans; Immunosuppressive Agents; Incidence; Kidney Transplantation; Lipids; Logistic Models; Male; Middle Aged; Mycophenolic Acid; Odds Ratio; Prednisone; Retrospective Studies; Risk Assessment; Risk Factors; Sirolimus; Tacrolimus; Time Factors; Treatment Outcome | 2011 |
New onset dyslipidemia after renal transplantation: is there a difference between tacrolimus and cyclosporine?
Topics: Adult; Body Mass Index; Cholesterol; Cyclosporine; Dyslipidemias; Hemoglobins; Humans; Hypertension; Immunosuppressive Agents; Kidney Transplantation; Lipids; Middle Aged; Postoperative Complications; Prevalence; Retrospective Studies; Tacrolimus; Triglycerides | 2006 |
Serum homocysteine levels in renal transplant recipients with and without hypercholesterolemia.
Topics: Adult; Age Factors; Biomarkers; Brazil; Cholesterol; Creatinine; Cyclosporine; Dyslipidemias; Epidemiologic Methods; Female; Homocysteine; Humans; Hypercholesterolemia; Hyperhomocysteinemia; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Proteinuria; Reference Values; Time Factors; Triglycerides | 2007 |
Dyslipidemia can reduce the immunosuppressive effects of cyclosporine.
Topics: Cells, Cultured; Cyclosporine; Dyslipidemias; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Leukocytes, Mononuclear; Lymphocyte Activation | 2008 |